Featured High-Impact Clinical Trials，1篇

时间

10月22日，8:00~9:30

地点

Bluebird Ballroom

专题

Opening Plenary

9:19 AM TH-OR111

Telitacicept for IgA Nephropathy: Final Two-Year Results of the Phase 3 TELIGAN Trial –

第一作者：Jicheng Lv（吕继成）

High-Impact Clinical Trials，1篇

时间

10月23日，10:30~12:30

地点

Bluebird Ballroom

专题

Oral Abstract Session

AM FR-OR102

HLX79 (E-602) Plus Rituximab Produces Fast and Durable Responses in Patients with Membranous Nephropathy

HLX79（E-602）联合利妥昔单抗使膜性肾病患者获得快速且持久的应答

第一作者：Zhilian Li（李志莲）报告时间：10月23日11:00~11:15

Late-Breaking Research Posters，17篇

时间

10月22日，10:00~12:00

地点

Exhibit Hall

TH-PO1250

Telitacicept in Patients with Refractory IgA Nephropathy: A Randomized, Open-Label Clinical Trial 泰它西普治疗难治性IgA肾病：随机开放标签临床试验

第一作者：Shang Liu

TH-PO1251

Sarcopenic Obesity and Gut-Derived Glycylvaline in Relation to Myocardial Fibrosis in Patients with ESRD on Maintenance Dialysis 维持性透析终末期肾病患者肌少性肥胖、肠道来源甘氨酰缬氨酸与心肌纤维化的关系

第一作者：Shang Liu

TH-PO1255

A Randomized, Placebo-Controlled Phase 2 Trial of a Long-Acting, C3-Targeting siRNA in IgA Nephropathy 长效靶向C3的siRNA治疗IgA肾病：Ⅱ期随机安慰剂对照试验

第一作者：Jicheng Lv吕继成

TH-PO1256

Telitacicept for IgA Nephropathy: Final Two-Year Results of the Phase 3 TELIGAN Trial 泰它西普治疗IgA肾病：Ⅲ期TELIGAN试验最终2年结果

第一作者：Jicheng Lv（吕继成）

TH-PO1259

Interim Phase 2 Results of SGB-9768, a Liver-Targeted GalNAc-siRNA-Targeting Complement C3, in IgA Nephropathy, C3 Glomerulopathy, and Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

肝脏靶向、靶向补体C3的GalNAc-siRNA SGB-9768治疗IgA肾病、C3肾小球病及原发性免疫复合物性膜增生性肾小球肾炎的Ⅱ期中期结果

第一作者：Minghui Zhao（赵明辉）

TH-PO1262

Efficacy and Safety of Eculizumab in Patients with Anti-Glomerular Basement Membrane Disease: An Investigator-Initiated, Open-Label, Phase 2 Clinical Trial 依库珠单抗治疗抗肾小球基底膜病的疗效与安全性：研究者发起的开放标签Ⅱ期临床试验

第一作者：Huang Kuang

TH-PO1264

Maintenance Rituximab Reduces Relapse in Phospholipase A2 Receptor (PLA2R)-Related Membranous Nephropathy: A Retrospective Cohort Study 利妥昔单抗维持治疗减少PLA2R相关膜性肾病复发：回顾性队列研究

第一作者：Jingyuan Xie

TH-PO1270

Biopsy-Guided Management Improves Renal Outcomes After Liver Transplantation: A Matched Cohort Study 肾活检指导的管理改善肝移植后肾脏结局：匹配队列研究

第一作者：Xiaoyan Liu

TH-PO1273

Niaoduqing Granules Improve Constipation in Patients with Peritoneal Dialysis: A Multicenter Prospective Controlled Study

尿毒清颗粒改善腹膜透析患者便秘：多中心前瞻性对照研究

第一作者：Miao Li

TH-PO1277

Efficacy and Safety of Gosicalcetide vs. Cinacalcet in Patients with Secondary Hyperparathyroidism Receiving Hemodialysis: Results from a Phase 3 Randomized Clinical Trial Gosicalcetide对比西那卡塞治疗血液透析继发性甲状旁腺功能亢进患者的疗效与安全性：Ⅲ期随机临床试验结果

第一作者：Xueqing Yu（余学清）

TH-PO1278

Long-Term Safety of Gosicalcetide in Patients with Secondary Hyperparathyroidism Receiving Hemodialysis Gosicalcetide在血液透析继发性甲状旁腺功能亢进患者中的长期安全性

第一作者：Li Zuo（左力）

TH-PO1279

Sodium Thiosulfate Attenuates Coronary Artery Calcification and Uremic Pruritus: A Randomized Crossover Trial 硫代硫酸钠减轻冠状动脉钙化及尿毒症瘙痒：随机交叉试验

第一作者：Chensi Sun

TH-PO1285

Proton Pump Inhibitor Use Is Associated with Improved Arteriovenous Fistula Patency in Patients with ESKD: A Retrospective Cohort Study with Experimental Support

质子泵抑制剂使用与终末期肾病患者动静脉内瘘通畅率改善相关：实验支持的回顾性队列研究

第一作者：Yuchi Tu

TH-PO1287

A Decellularized Biological Vascular Graft for Hemodialysis Access: 18-Month First-in-Human Clinical Outcomes of LineMatrix

去细胞生物血管移植物用于血液透析通路：LineMatrix首次人体应用18个月临床结局

第一作者：Qiu Xuefeng

TH-PO1288

Clinical Evaluation of a Novel Polyethersulfone Hemodiafiltration Filter: A Multicenter Randomized Crossover Noninferiority Trial 新型聚醚砜血液透析滤过器的临床评价：多中心随机交叉非劣效性试验

F第一作者：anna Liu（刘璠娜）

TH-PO1296

First-in-Human Study of SK-09, a Novel Transient Receptor Potential iChannel-5 Inhibitor: Safety, Tolerability, and Pharmacokinetics in Healthy Participants 新型瞬时受体电位通道5抑制剂SK-09首次人体研究：健康受试者的安全性、耐受性及药代动力学

第一作者：Du Ying（杜颖）

TH-PO1298

Digital Cognitive Behavioral Therapy for Hyperkalemia in Patients on Maintenance Hemodialysis: A Prospective, Single-Center, Randomized Controlled Trial 数字化认知行为疗法治疗维持性血液透析患者高钾血症：前瞻性单中心随机对照试验

第一作者：Hongli Lin（林洪丽）

Oral Abstract Session，23篇

“肾医线”读者专属微信群建好了，快快加入吧。扫描“肾医线”小助手二维码（微信号：nephro-online），回复“肾医线读者”，ta会尽快拉您入群滴！

（来源：《肾医线》编辑部）